by Jordana Choucair | Mar 22, 2022 | Life Sciences
Pfizer Inc. said it struck a deal to sell up to 4 million courses of its COVID-19 antiviral pill at a “not-for-profit price” to the United Nations Children’s Fund, which will distribute the treatment to 95 lower-income countries. The drugmaker will...
by Jordana Choucair | Mar 21, 2022 | Life Sciences
A new study published in JAMA Network Open found that the Johnson & Johnson (J&J) COVID-19 vaccine remains durable and effective. According to the research, the J&J shot was 76 percent effective in preventing COVID-19 infections and 81 percent effective in...
by Jordana Choucair | Mar 21, 2022 | Life Sciences
AstraZeneca announced its antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron COVID-19 variants, including the BA.2 sub-variant. Britain’s drug regulator approved the therapy, called Evusheld, last week for preventing...
by Jordana Choucair | Mar 18, 2022 | Life Sciences
The Medicines Patent Pool (MPP), a U.N.-backed organization, announced that 35 manufacturers agreed to produce generic forms of Paxlovid – Pfizer’s oral antiviral treatment for COVID-19. Six companies will focus on producing the substance of the drug, nine...
by Jordana Choucair | Mar 18, 2022 | Life Sciences
Moderna asked the FDA for emergency authorization of a second booster of its COVID-19 vaccine for all adults. The request is significantly broader than Pfizer’s and BioNTech’s request, which asked the agency to authorize its second booster for adults 65 and older....
by Jordana Choucair | Mar 16, 2022 | Life Sciences
Pfizer and BioNTech have applied for emergency use authorization of a fourth booster dose of their Covid-19 vaccine. The companies said the additional dose is for adults 65 and older who have gotten a booster dose of any of the authorized or approved vaccines....
Recent Comments